1015 Walnut Street
Suite 115
Philadelphia, PA 19107
(215) 955-4755
(215) 923-7583 fax
Suite 115
Philadelphia, PA 19107
(215) 955-4755
(215) 923-7583 fax
Most Recent Peer-reviewed Publications
- Economic evaluations alongside effectiveness trials
- Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: Results from the CHARISMA trial
- Long-term cost-effectiveness of clopidogrel in STEMI patients
- The risk of cardiovascular events in primary care patients following an episode of severe hypertension
- FDAMA 1997 section 114: Another look
- One-year costs in patients with a history of or at risk for atherothrombosis in the United States.
- Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: An economic evaluation for Sweden
- Patient-reported outcome instrument selection: Designing a measurement strategy
- The effect of eflornithine 13.9% cream on the bother and discomfort due to hirsutism
- Multiple co-primary endpoints: Medical and statistical solutions - A report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America
- Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair
- Assessing health state utilities in elderly patients at cardiovascular risk
- Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation
- Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
- Caring for Hypertension on Initiation: Costs and Effectiveness (CHOICE): A naturalistic design and rationale for the study of patterns of care in hypertension
- Allocating funds for cardiovascular 081B disease prevention in light of the NCEP ATP III guidelines
- Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR task force on good research practices - Modeling studies
- Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: The outcomes research and economic analysis components of the PROSPER trial
- Regulatory issues for health-related quality of life - PhRMA Health Outcomes Committee Workshop, 1999
- The cardiovascular event reduction tool (CERT) - A simplified cardiac risk prediction model developed from the West of Scotland Coronary Prevention Study (WOSCOPS)